These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 7637045

  • 1. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O, Hanani J, Shalhav A, Vardi Y, Goldwasser B.
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [Abstract] [Full Text] [Related]

  • 2. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A, Casabé A, Chéliz G, Romano S, Rey H, Fredotovich N.
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A, Casabé A, Chéliz G, Romano S, Fredotovich N.
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [Abstract] [Full Text] [Related]

  • 4. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R, Asakawa M, Kawashima H, Yoshimura R, Maekawa T, Kashiwara N, Tanaka H, Nishio S.
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [Abstract] [Full Text] [Related]

  • 5. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Zaher TF.
    Int Urol Nephrol; 1998 Feb; 30(2):193-6. PubMed ID: 9607891
    [Abstract] [Full Text] [Related]

  • 6. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W, de la Fuente RB, Lycklama à Nijeholt AA, Vermeij P, Zwartendijk J.
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [Abstract] [Full Text] [Related]

  • 7. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM, Stevenson RW, Szasz G.
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [Abstract] [Full Text] [Related]

  • 8. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y, Lidgi S, Moskovitz B, Levin RD.
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [Abstract] [Full Text] [Related]

  • 9. [Prostaglandin E1 in erectile dysfunction].
    Porst H.
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [Abstract] [Full Text] [Related]

  • 10. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R, Melman A.
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [Abstract] [Full Text] [Related]

  • 11. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH.
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [Abstract] [Full Text] [Related]

  • 12. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A, Schramek P.
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [Abstract] [Full Text] [Related]

  • 13. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP, Engel RM, Smolev JK, Brendler CB.
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E, Israilov S, Shmueli J, Simon D, Baniel J, Livne P.
    Harefuah; 1998 May 01; 134(9):673-8, 750. PubMed ID: 10909609
    [Abstract] [Full Text] [Related]

  • 15. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S, Iwai Y, Yasumoto R, Matsuda J, Kawano M, Omachi T, Kono T, Yamamoto S, Sakakura T, Minami H.
    Hinyokika Kiyo; 1994 Jan 01; 40(1):37-41. PubMed ID: 7509119
    [Abstract] [Full Text] [Related]

  • 16. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K, Chen Jiménez J, Tamayo JC, Rodríguez Antolín A, Alvarez González E.
    Actas Urol Esp; 1992 Mar 01; 16(3):208-16. PubMed ID: 1621545
    [Abstract] [Full Text] [Related]

  • 17. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K, Brekke I, Christiansen E.
    Int J Impot Res; 1996 Mar 01; 8(1):9-16. PubMed ID: 8735188
    [Abstract] [Full Text] [Related]

  • 18. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W, Lycklama à Nijeholt AA, Kropman RF, Vermeij P, Zwartendijk J.
    Eur Urol; 1994 Mar 01; 26(4):319-21. PubMed ID: 7713130
    [Abstract] [Full Text] [Related]

  • 19. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
    Sarosdy MF, Hudnall CH, Erickson DR, Hardin TC, Novicki DE.
    J Urol; 1989 Mar 01; 141(3):551-3. PubMed ID: 2645420
    [Abstract] [Full Text] [Related]

  • 20. Intracavernosal injection therapy for impotence: preliminary results.
    Gilling PJ, Wright WL, Gray JM.
    N Z Med J; 1988 Jun 22; 101(848):423-4. PubMed ID: 3393333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.